for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Applied Genetic Technologies Corp

AGTC.OQ

Latest Trade

3.24USD

Change

0.07(+2.21%)

Volume

19,400

Today's Range

3.13

 - 

3.34

52 Week Range

2.26

 - 

7.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

AGTC And Otonomy Announce Strategic Collaboration To Develop, Commercialize Gene Therapy For Congenital Hearing Loss

Oct 1 (Reuters) - Otonomy Inc <OTIC.O>::AGTC AND OTONOMY ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE GENE THERAPY FOR CONGENITAL HEARING LOSS.OTONOMY INC - UNDER COLLABORATION AGREEMENT, PARTIES WILL EQUALLY SHARE PROGRAM COSTS AND PROCEEDS.

AGTC Posts Fourth Quarter Results

Sept 26 (Reuters) - Applied Genetic Technologies Corp <AGTC.O>::AGTC ANNOUNCES FINANCIAL RESULTS AND BUSINESS UPDATE FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED JUNE 30, 2019.APPLIED GENETIC TECHNOLOGIES - PROMISING TOPLINE 6-MONTH DOSE ESCALATION DATA FROM ONGOING PHASE 1/2 CLINICAL TRIALS FOR X-LINKED RETINITIS PIGMENTOSA.APPLIED GENETIC TECHNOLOGIES CORP - PRELIMINARY THREE-MONTH XLRP DOSE EXPANSION DATA DEMONSTRATES IMPROVEMENT IN 50% OF CENTRALLY DOSED PATIENTS.APPLIED GENETIC TECHNOLOGIES CORP - EARLY DATA FROM BOTH ACHROMATOPSIA (ACHM) PROGRAMS INDICATE BIOLOGIC ACTIVITY.APPLIED GENETIC TECHNOLOGIES CORP - BOTH DATA SETS DEMONSTRATED A FAVORABLE SAFETY PROFILE.APPLIED GENETIC TECHNOLOGIES CORP - REVENUE WAS $0.4 MILLION FOR Q4 OF 2019.APPLIED GENETIC TECHNOLOGIES CORP - AS OF JUNE 30, 2019, COMPANY'S CASH, CASH EQUIVALENTS, AND INVESTMENTS AMOUNTED TO $82.0 MILLION.APPLIED GENETIC TECHNOLOGIES CORP - QTRLY LOSS PER SHARE $0.58.APPLIED GENETIC TECHNOLOGIES CORP - COMPANY EXPECTS TOTAL CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2020 TO BE BETWEEN $30 AND $40 MILLION.

Applied Genetic Technologies Corp QTRLY Earnings Per Share $0.63

Applied Genetic Technologies Corp <AGTC.O>::APPLIED GENETIC TECHNOLOGIES CORP - TOTAL REVENUE FOR THREE MONTHS ENDED MARCH 31 WERE $21.3 MILLION COMPARED TO $3.6 MILLION IN COMPARABLE PERIOD IN 2018.APPLIED GENETIC TECHNOLOGIES CORP QTRLY EARNINGS PER SHARE $0.63.APPLIED GENETIC TECHNOLOGIES CORP - COMPANY EXPECTS TOTAL CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2019 TO BE BETWEEN $75 AND $80 MILLION.

Privium Fund Management BV Reports 7.3 Pct Passive Stake In Applied Genetic Technologies

March 26 (Reuters) - Applied Genetic Technologies Corp <AGTC.O>::PRIVIUM FUND MANAGEMENT BV REPORTS 7.3 PERCENT PASSIVE STAKE IN APPLIED GENETIC TECHNOLOGIES CORP AS OF MARCH 14 - SEC FILING.

Applied Genetic Technologies Quarterly Revenue $5.9 Million Versus $15.2 Million

Feb 7 (Reuters) - Applied Genetic Technologies Corp <AGTC.O>::QUARTERLY REVENUE $5.9 MILLION VERSUS $15.2 MILLION.APPLIED GENETIC TECHNOLOGIES - EXPECT OPTOGENETICS PARTNER, TO FILE AN INDA WITH FDA IN FIRST HALF OF 2019.TOTAL REVENUE WAS $5.9 MILLION FOR THREE MONTHS ENDED DECEMBER 31, 2018 COMPARED TO $4.9 MILLION.QTRLY LOSS PER SHARE $0.23.

AGTC Reports Topline Interim 6 Month Data From Phase 1/2 X-Linked Retinoschisis Clinical Study

Dec 12 (Reuters) - Applied Genetic Technologies Corp <AGTC.O>::AGTC ANNOUNCES TOPLINE INTERIM SIX-MONTH DATA FROM PHASE 1/2 X-LINKED RETINOSCHISIS CLINICAL STUDY; TERMINATION OF BIOGEN COLLABORATION.APPLIED GENETIC- RESULTS FROM STUDY SHOW RAAV2TYF-CB-HRS1 GENERALLY SAFE, WELL-TOLERATED, BUT NO SIGNS OF CLINICAL ACTIVITY WERE OBSERVED AT 6-MONTHS.APPLIED GENETIC TECHNOLOGIES - TO REGAIN RIGHTS TO FIVE CLINICAL AND PRECLINICAL DEVELOPMENT PROGRAMS; BIOGEN TERMINATES COLLABORATION AGREEMENT.APPLIED GENETIC TECHNOLOGIES - TO REGAIN RIGHTS TO FIVE CLINICAL & PRECLINICAL DEVELOPMENT PROGRAMS; BIOGEN TERMINATES COLLABORATION AGREEMENT.APPLIED GENETIC - ON SCHEDULE TO ADVANCE ITS PHASE 1/2 CLINICAL STUDIES IN ACHROMATOPSIA,X-LINKED RETINITIS PIGMENTOSA; 3 DATA RELEASES SEEN IN 2019.APPLIED GENETIC TECHNOLOGIES CORP - BIOGEN'S TERMINATION OF COLLABORATION AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2019.APPLIED GENETIC TECHNOLOGIES - WILL DETERMINE NEXT STEPS FOR THREE DISCOVERY PROGRAMS OVER NEXT SEVERAL MONTHS.APPLIED GENETIC TECHNOLOGIES - PREVIOUS FINANCIAL GUIDANCE, EVEN IN LIGHT OF BIOGEN'S TERMINATION OF COLLABORATION AGREEMENT, REMAINS UNCHANGED.APPLIED GENETIC TECHNOLOGIES CORP - AS OF SEPT 30, 2018, CO'S CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $105.4 MILLION.APPLIED GENETIC TECHNOLOGIES - EXPECTS TOTAL CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2019, TO BE BETWEEN $65 AND $75 MILLION.

Applied Genetic Technologies Qtrly EPS $0.07

Nov 8 (Reuters) - Applied Genetic Technologies Corp <AGTC.O>::QUARTERLY REVENUE $14 MILLION VERSUS $10.3 MILLION.QTRLY EARNINGS PER SHARE $0.07.

Applied Genetic Technologies Q4 Revenue $5.4 Mln Vs $39.5 Mln

Sept 10 (Reuters) - Applied Genetic Technologies Corp <AGTC.O>::Q4 REVENUE $5.4 MILLION VERSUS $39.5 MILLION.Q4 REVENUE VIEW $8.5 MILLION -- THOMSON REUTERS I/B/E/S.EXPECTS TOTAL CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2019 TO BE BETWEEN $65 AND $75 MILLION.

Applied Genetic Files For Mixed Shelf Of Upto $125 Million

May 30 (Reuters) - Applied Genetic Technologies Corp <AGTC.O>::APPLIED GENETIC TECHNOLOGIES CORP FILES FOR MIXED SHELF OF UPTO $125 MILLION - SEC FILING.

Applied Genetic Technologies Qtrly Rev Fell To $3.6 Mln

May 8 (Reuters) - Applied Genetic Technologies Corp <AGTC.O>::QUARTERLY REVENUE $3.6 MILLION VERSUS $8.4 MILLION .QTRLY LOSS PER SHARE $0.45.Q3 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up